BlackRock Institutional Trust’s Regulus Therapeutics RGLS Stock Holding History

BlackRock Institutional Trust’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.74M	Buy	6,429 +16	+0.2%	+$5.2K	﹤0.01%	3108
2016 Q3	$2.54M	Buy	6,413 +149	+2%	+$61.3K	﹤0.01%	2959
2016 Q2	$2.17M	Buy	6,264 +485	+8%	+$347K	﹤0.01%	3003
2016 Q1	$4.81M	Sell	5,779 -51	-0.9%	-$40.6K	﹤0.01%	2687
2015 Q4	$6.1M	Buy	5,830 +158	+3%	+$158K	﹤0.01%	2605
2015 Q3	$4.45M	Buy	5,672 +653	+13%	+$670K	﹤0.01%	2779
2015 Q2	$6.6M	Buy	5,019 +962	+24%	+$1.55M	﹤0.01%	2641
2015 Q1	$8.25M	Buy	4,057 +1,398	+53%	+$3.04M	﹤0.01%	2513
2014 Q4	$5.12M	Buy	2,659 +1,706	+179%	+$3.03M	﹤0.01%	2723
2014 Q3	$781K	Sell	953 -413	-30%	-$349K	﹤0.01%	3394
2014 Q2	$1.32M	Buy	1,366 +228	+20%	+$195K	﹤0.01%	3349
2014 Q1	$1.23M	Sell	1,138 -893	-44%	-$990K	﹤0.01%	3347
2013 Q4	$1.8M	Buy	2,031 +297	+17%	+$256K	﹤0.01%	3208
2013 Q3	$1.96M	Buy	1,734 +173	+11%	+$204K	﹤0.01%	3141
2013 Q2	$1.84M	Buy	+1,561	New	+$1.48M	﹤0.01%	3121

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock Institutional Trust's RGLS Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Regulus Therapeutics (RGLS) stake by 0.25% in Q4 2016, buying an estimated $5.2K and bringing the position to 6,429 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3108.

BlackRock Institutional Trust first reported a position in RGLS in Q2 2013 and has held it in 15 quarters since. The position peaked at $8.25M in Q1 2015. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

BlackRock Institutional Trust held 6,429 shares of Regulus Therapeutics worth $1.74M as of Q4 2016.
BlackRock Institutional Trust bought 16 Regulus Therapeutics shares in Q4 2016, an estimated $5.2K.
Regulus Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3108 holding.
BlackRock Institutional Trust first reported a position in Regulus Therapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Regulus Therapeutics position peaked at $8.25M in Q1 2015.
68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.